Imagion Biosystems Limited has announced Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B, for the quarter ended 31 March, 2018.
Read Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer